Oral Corticosteroid Dependent Asthma research hub

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase III Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma (SUNRISE)

This study is testing a new medicine, Tezepelumab, for adults with severe asthma who need to take steroid tablets. It aims to see if the medicine can help them reduce their steroid dose while keeping their asthma under control.